...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Tensha Therapeutics sold to Roche
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Interesting, though it's one of those Contingent Value Rights (CVR) deals. I'm not a fan of CVRs but it might be difficult to do better in the sale of a Phase I company.

The Bradner factor: Roche bags a BET inhibitor in $535M Tensha buyout
January 10, 2016 | By John Carroll

http://www.fiercebiotech.com/story/bradner-factor-roche-bags-bet-inhibitor-535m-tensha-buyout/2016-01-10

Shadowy Shares: The Dark Side of Contingent Value Rights
May 9, 2011
Forbes

http://www.forbes.com/sites/greatspeculations/2011/05/09/shadowy-shares-the-dark-side-of-contingent-value-rights/

5 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply